SMILES,Name,Conditions,NCT_Number,Phases,Unapproval Probability,Approval Probability
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O,_BIVALIRUDIN,ST ELEVATION MYOCARDIAL INFARCTION,NCT03822975,Not Applicable,0.1442993040697504,0.85570069593025
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.02731426105741913,0.9726857389425808
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_PROGESTERONE,"INFERTILITY, FEMALE",NCT04259996,,0.0615550541793449,0.9384449458206552
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,"INFERTILITY, FEMALE",NCT04259996,,0.08241457365033282,0.9175854263496672
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,URINARY TRACT INFECTIONS,NCT04301934,Not Applicable,0.004017967326590305,0.9959820326734098
CC(=O)[O-],_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.04197329062054556,0.9580267093794546
CC(=O)[O-],_ACETATE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.15524635463798891,0.8447536453620108
CC(=O)[O-],_ACETATE,DEPRESSION,NCT02837432,Early Phase 1,0.06008160765428384,0.9399183923457164
CC(=O)[O-],_ACETATE,HIV-1 INFECTION,NCT03536234,Phase 2,0.0987375908128636,0.9012624091871364
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.11706854416386164,0.8829314558361382
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,NON SMALL CELL LUNG CANCER,NCT02666105,Phase 2,0.2660862089325055,0.7339137910674941
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,OVARIAN CANCER,NCT04460807,Phase 3,0.0984666990199386,0.9015333009800612
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,_FULVESTRANT,NEOPLASMS,NCT02530411,Phase 2,0.4389847740085995,0.5610152259914005
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,OVARIAN CANCER,NCT03378297,Early Phase 1,0.17963535758153104,0.8203646424184692
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.04299493385405324,0.9570050661459468
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.12231793773389155,0.8776820622661085
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.24409388045902336,0.7559061195409764
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,METASTATIC PROSTATE CANCER,NCT03764540,Phase 2,0.07229895505078554,0.9277010449492143
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,IDIOPATHIC MEMBRANOUS NEPHROPATHY,NCT03549663,Not Applicable,0.0007011427935329079,0.999298857206467
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.11714756609178842,0.8828524339082117
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.0588713291303666,0.9411286708696334
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,METASTATIC PROSTATE CANCER,NCT04262154,Phase 2,0.2647054329839713,0.7352945670160287
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,_CABAZITAXEL,METASTATIC PROSTATE CANCER,NCT03764540,Phase 2,0.23891296141516366,0.7610870385848361
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,_ABIRATERONE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.18634439766574493,0.8136556023342549
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,_ABIRATERONE_ACETATE,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.2563793033897926,0.7436206966102076
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,_FLUTAMIDE,PCOS,NCT00930228,Phase 1,0.18046871048894506,0.8195312895110551
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASMS,NCT03693612,Phase 2,0.2927517641732681,0.7072482358267318
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,METASTATIC PROSTATE CANCER,NCT03764540,Phase 2,0.2602497575265814,0.7397502424734186
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASM METASTASIS,NCT00781612,Phase 2,0.21011077051447635,0.7898892294855234
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,CASTRATION-RESISTANT PROSTATIC CANCER,NCT04404140,Phase 1,0.12088226034719585,0.8791177396528042
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,_TRIPTORELIN,HIV-1 INFECTION,NCT03536234,Phase 2,0.16135485180150916,0.8386451481984908
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",NCT03431350,Phase 1|Phase 2,0.3154430514639662,0.6845569485360338
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PROSTATE CANCER,NCT04194554,Phase 1|Phase 2,0.351454270234668,0.6485457297653321
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,BREAST CANCER,NCT02826512,Phase 2,0.1989205052397313,0.8010794947602687
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,OVARIAN NEOPLASMS,NCT03955471,Phase 2,0.43666417457535295,0.563335825424647
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACYCLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.11773161858995225,0.8822683814100479
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACICLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.11773161858995225,0.8822683814100479
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.12370474874071676,0.8762952512592832
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,OVARIAN CANCER,NCT03464201,Phase 2,0.13741248471877554,0.8625875152812243
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,METASTATIC PROSTATE CANCER,NCT04179864,Phase 1,0.2438321379327151,0.7561678620672849
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,BREAST CANCER,NCT02955394,Phase 2,0.230577317136764,0.7694226828632357
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,PROSTATE ADENOCARCINOMA,NCT03829930,Phase 1,0.3074345179928945,0.6925654820071054
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.31907309389070965,0.6809269061092903
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,NEOPLASMS,NCT03967223,Phase 2,0.2783906687213333,0.7216093312786666
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PROSTATE CANCER,NCT03089203,Phase 1,0.4016239210263168,0.5983760789736831
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,METASTATIC RENAL CELL CARCINOMA,NCT02926053,Phase 1,0.3206881724999216,0.6793118275000782
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,NCT04227275,Phase 1,0.4318765684686518,0.5681234315313481
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.4910321109827224,0.5089678890172775
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,MULTIPLE SCLEROSIS,NCT03477500,Phase 3,0.04126950711210768,0.9587304928878924
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,BREAST CANCER,NCT02897700,Phase 1,0.10229241293586724,0.8977075870641329
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.473362256199435,0.526637743800565
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,IDIOPATHIC MEMBRANOUS NEPHROPATHY,NCT03549663,Not Applicable,0.0008212005108556834,0.9991787994891445
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.18554249440375364,0.8144575055962463
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,KIDNEY FAILURE,NCT04258423,Phase 3,0.0048070671114011825,0.9951929328885988
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,ACUTE MYELOID LEUKEMIA,NCT03467386,Phase 1,0.11788933671458855,0.8821106632854113
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.8155089292618241,0.18449107073817614
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,HIV INFECTIONS|AIDS,NCT03517631,Phase 1,0.4193299044873236,0.5806700955126766
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.6992133262453439,0.30078667375465584
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,NEOPLASMS,NCT03967223,Phase 2,0.8196611419270297,0.1803388580729704
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,METASTATIC RENAL CELL CARCINOMA,NCT02926053,Phase 1,0.736109645716442,0.2638903542835578
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,NCT04227275,Phase 1,0.9312934193435868,0.06870658065641302
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.9781177935940738,0.021882206405925798
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,"CARCINOMA, RENAL CELL",NCT04195750,Phase 3,0.02351353035928597,0.9764864696407138
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,KIDNEY FAILURE,NCT04258423,Phase 3,0.06345515653134423,0.936544843468656
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,END STAGE RENAL DISEASE,NCT03413722,,0.2818420283339934,0.7181579716660066
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,BLADDER CANCER,NCT02885974,Phase 1,0.6998612266765136,0.30013877332348665
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NON SMALL CELL LUNG CANCER,NCT02477826,Phase 3,0.23435874703658655,0.7656412529634135
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASMS,NCT03693612,Phase 2,0.2283976098008029,0.7716023901991969
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASM METASTASIS,NCT00781612,Phase 2,0.2069407907338908,0.7930592092661091
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,BLADDER CANCER,NCT04060459,Phase 2,0.12273635070545012,0.8772636492945497
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.3824336125342023,0.617566387465798
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,NON SMALL CELL LUNG CANCER,NCT03334617,Phase 2,0.3824443325909033,0.6175556674090971
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,OVARIAN CANCER,NCT03378297,Early Phase 1,0.20176569533861205,0.798234304661388
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER,NCT03810105,Phase 2,0.39936649705906335,0.6006335029409366
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,COLORECTAL CANCER,NCT04166435,Phase 2,0.3878309926669217,0.6121690073330783
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER METASTATIC,NCT03434158,Phase 2,0.2452833795845712,0.754716620415429
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE,NCT03047135,Phase 2,0.4371098368563049,0.5628901631436951
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_VASOPRESSIN,HYPERTENSION,NCT04170751,Not Applicable,0.09102446103585607,0.908975538964144
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,NON SMALL CELL LUNG CANCER,NCT03661567,Phase 2,0.030211487557013906,0.969788512442986
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.3881056986279831,0.6118943013720166
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PNEUMONIA,NCT03852537,Phase 2,0.10014925073117384,0.8998507492688261
NC[C@H](O)c1ccc(O)c(O)c1,_NOREPINEPHRINE,HYPERTENSION,NCT04170751,Not Applicable,0.09446729436852064,0.9055327056314794
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,"INFERTILITY, FEMALE",NCT04518189,Not Applicable,0.016124648868155008,0.983875351131845
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,CONTRACEPTION,NCT02799641,Not Applicable,0.006956701689837717,0.9930432983101624
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,PERITONEAL DIALYSIS-ASSOCIATED PERITONITIS,NCT03685747,Phase 1,0.229644751158252,0.7703552488417479
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,_GENTAMICIN,GONORRHEA,NCT03294395,Phase 3,0.05389486177810719,0.9461051382218928
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.2941529209659733,0.7058470790340268
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,ACUTE MYELOID LEUKEMIA,NCT02782546,Phase 2,0.3092488464875792,0.6907511535124208
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,BREAST CANCER,NCT01646034,Phase 3,0.210144215365608,0.7898557846343921
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.7519576560792964,0.2480423439207037
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.20426568329276076,0.795734316707239
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.25373253058571194,0.7462674694142878
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,_ELTROMBOPAG,ACUTE MYELOID LEUKEMIA,NCT03603795,Phase 2,0.3163806449289885,0.6836193550710112
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.8426924070431059,0.15730759295689398
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,ACUTE MYELOID LEUKEMIA,NCT02771197,Phase 2,0.8806260147093952,0.1193739852906047
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,_VEDOTIN,NON SMALL CELL LUNG CANCER,NCT03539536,Phase 2,0.5265345599826508,0.4734654400173492
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,DEPRESSION,NCT02837432,Early Phase 1,0.11732410830626128,0.8826758916937386
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,PROSTATE CANCER,NCT00859781,Phase 2,0.18042523936699945,0.8195747606330006
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,SEPSIS,NCT04160676,Not Applicable,0.010230129921739555,0.9897698700782604
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,HIV INFECTION,NCT03237689,Early Phase 1,0.23027383466356896,0.769726165336431
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,_ETOPOSIDE,NON SMALL CELL LUNG CANCER,NCT03840902,Phase 2,0.25921258634251004,0.7407874136574901
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,PROSTATIC NEOPLASMS,NCT04034095,,0.0819469792421291,0.9180530207578708
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,RECURRENT MISCARRIAGE,NCT03902912,Phase 3,0.0578140025967549,0.9421859974032452
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,_AZATHIOPRINE,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.3684752970077937,0.6315247029922062
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER,NCT03513211,Phase 1|Phase 2,0.1966110147008214,0.8033889852991785
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.3923467061325251,0.6076532938674749
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER RECURRENT,NCT04011410,Phase 2,0.4299267216342183,0.5700732783657816
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,TYPE 1 DIABETES,NCT03428945,Phase 2,0.1762684135414821,0.8237315864585177
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,RECURRENT PREGNANCY LOSS,NCT03305263,Phase 3,0.03715081397638267,0.9628491860236172
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,NEPHROLITHIASIS,NCT03584373,Phase 3,0.015851546360619074,0.9841484536393807
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.21430806036956376,0.7856919396304365
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,ANALGESIA,NCT03955211,Phase 2,0.3998239978315465,0.6001760021684535
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,DIABETIC FOOT,NCT03871049,Not Applicable,0.03658357957896153,0.9634164204210386
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,_TOLVAPTAN,"POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT",NCT02847624,,0.08524898071359764,0.9147510192864022
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,_DEXTROSE,HYSTERECTOMY,NCT03719755,Not Applicable,0.13337890956237622,0.866621090437624
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,_DEXTROSE,END-STAGE KIDNEY DISEASE,NCT02694068,,0.5273346530909834,0.4726653469090168
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,_CABERGOLINE,ENDOMETRIOSIS,NCT03928288,Phase 2,0.1127829588037916,0.8872170411962083
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,POSTPARTUM HAEMORRHAGE,NCT03434444,Not Applicable,0.2717622718898478,0.7282377281101522
CC(=O)Nc1nnc(S(N)(=O)=O)s1,_ACETAZOLAMIDE,"HYPERTENSION, PULMONARY",NCT02755298,Phase 2|Phase 3,0.13946699143883273,0.8605330085611673
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MULTIPLE SCLEROSIS,NCT04035889,Not Applicable,0.1457128866189022,0.8542871133810978
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MIGRAINE DISORDERS,NCT03597529,Phase 2,0.11169576658282476,0.8883042334171752
N[C@@H](Cc1c[nH]cn1)C(=O)O,_HISTIDINE,"RENAL INSUFFICIENCY, CHRONIC",NCT02947750,Phase 2,0.4993284966608419,0.5006715033391581
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,"RENAL INSUFFICIENCY, CHRONIC",NCT02947750,Phase 2,0.3735532106289372,0.6264467893710628
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,ANEMIA,NCT04404751,Not Applicable,0.029585534296564176,0.9704144657034358
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,ANEMIA,NCT02757898,Phase 1,0.5491393325994157,0.4508606674005843
C[N+](C)(C)CCO,_CHOLINE,PROSTATE ADENOCARCINOMA,NCT03404648,Phase 3,0.6504542887911497,0.3495457112088504
C[N+](C)(C)CCO,_CHOLINE,GESTATIONAL DIABETES,NCT04302168,Not Applicable,0.1782647145929395,0.8217352854070605
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,_AZITHROMYCIN,BACTERIAL INFECTIONS,NCT03925480,Phase 3,0.0037942534099180475,0.9962057465900821
NC(=O)c1cccnc1,_NICOTINAMIDE,PARKINSON'S DISEASE,NCT03568968,Not Applicable,0.3710416014288255,0.6289583985711747
NC(=O)c1cccnc1,_NICOTINAMIDE,SICKLE CELL DISEASE,NCT04055818,Phase 1,0.28498586940453785,0.7150141305954624
NC(=O)c1cccnc1,_NICOTINAMIDE,PREECLAMPSIA,NCT03419364,Phase 2,0.400953065235601,0.5990469347643992
NC(=O)c1cccnc1,_NICOTINAMIDE,HYPERTENSION,NCT04112043,Phase 1,0.34580146639799897,0.654198533602001
NC(=O)c1cccnc1,_NIACINAMIDE,PARKINSON'S DISEASE,NCT03568968,Not Applicable,0.3710416014288255,0.6289583985711747
NC(=O)c1cccnc1,_NIACINAMIDE,SICKLE CELL DISEASE,NCT04055818,Phase 1,0.28498586940453785,0.7150141305954624
NC(=O)c1cccnc1,_NIACINAMIDE,PREECLAMPSIA,NCT03419364,Phase 2,0.400953065235601,0.5990469347643992
NC(=O)c1cccnc1,_NIACINAMIDE,HYPERTENSION,NCT04112043,Phase 1,0.34580146639799897,0.654198533602001
O=C([O-])C[N+]12CC[N+]3(CC(=O)[O-])CC[N+]4([C@@H](CO)[C@@H](O)CO)CC[N+](CC(=O)[O-])(CC1)[Gd-]234,_GADOBUTROL,PROSTATE ADENOCARCINOMA,NCT03404648,Phase 3,0.40487104499269255,0.5951289550073074
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,BLADDER CANCER,NCT04046094,Phase 1|Phase 2,0.5040243776164034,0.4959756223835966
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,SEPSIS,NCT04160676,Not Applicable,0.04327868870631985,0.95672131129368
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,SEPSIS,NCT04160676,Not Applicable,0.06562103232665427,0.9343789676733458
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,_PAZOPANIB,KIDNEY CANCER,NCT03571438,Not Applicable,0.18391301747293304,0.8160869825270667
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,COLORECTAL CANCER,NCT04166435,Phase 2,0.6770548420149944,0.3229451579850054
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,_HYDROXYCHLOROQUINE_SULFATE,PROSTATE CANCER RECURRENT,NCT04011410,Phase 2,0.4971424208784682,0.5028575791215317
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,BREAST CANCER,NCT02790580,Phase 2,0.14628376915811742,0.8537162308418828
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,KIDNEY CANCER,NCT03571438,Not Applicable,0.10828623912738497,0.8917137608726149
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,RENAL CELL CARCINOMA,NCT02919371,Phase 1|Phase 2,0.07963642269633446,0.9203635773036656
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_TEMSIROLIMUS,KIDNEY CANCER,NCT03571438,Not Applicable,0.5873159078421991,0.41268409215780105
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,OVARIAN CANCER,NCT04337632,Phase 3,0.10635137597130256,0.8936486240286974
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,LIVER CIRRHOSIS,NCT02642874,Phase 3,0.0426260095361387,0.9573739904638612
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,CHRONIC KIDNEY DISEASES,NCT04120922,Not Applicable,0.1890014469161572,0.8109985530838429
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,OSTEOPOROSIS,NCT04550078,Not Applicable,0.1014908249525386,0.8985091750474613
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,_CALCIFEDIOL,MYOCARDIAL INFARCTION,NCT02548364,Phase 3,0.023421573002311503,0.9765784269976884
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,_LUTEIN,PROSTATE CANCER,NCT04136353,Phase 3,0.17753525932272962,0.8224647406772704
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,PROSTATE CANCER,NCT03769766,Phase 3,0.1560136090579341,0.8439863909420658
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,BREAST CANCER,NCT03980509,Phase 1,0.5334582213791985,0.4665417786208016
N[C@@H](CS)C(=O)O,_CYSTEINE,CANNABIS USE DISORDER,NCT03055377,Phase 2|Phase 3,0.18091229657086105,0.8190877034291391
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,HIV INFECTION,NCT04425902,Phase 1,0.311822669297195,0.6881773307028051
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,_VITAMIN_E,BREAST CANCER,NCT04463459,Not Applicable,0.16542947821397302,0.8345705217860268
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04011930,Phase 2,0.03583126675012361,0.9641687332498764
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,END STAGE RENAL DISEASE,NCT04145492,Phase 2|Phase 3,0.022763694111363485,0.9772363058886364
CN(C)C(=N)NC(=N)N,_METFORMIN,NON SMALL CELL LUNG CANCER,NCT03874000,Phase 2,0.1903270408679586,0.8096729591320414
CN(C)C(=N)NC(=N)N,_METFORMIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.08335001449621919,0.9166499855037809
CN(C)C(=N)NC(=N)N,_METFORMIN,BREAST CANCER,NCT04559308,Phase 2,0.00433544856979865,0.9956645514302014
CN(C)C(=N)NC(=N)N,_METFORMIN,HIV/AIDS,NCT04500678,Phase 2|Phase 3,0.05353308933719817,0.946466910662802
CN(C)C(=N)NC(=N)N,_METFORMIN,HEART FAILURE,NCT03331861,Phase 2,0.014929546455498566,0.9850704535445014
CN(C)C(=N)NC(=N)N,_METFORMIN,"RENAL INSUFFICIENCY, CHRONIC",NCT02895750,Phase 2,0.0394341947541311,0.9605658052458688
CN(C)C(=N)NC(=N)N,_METFORMIN,RHEUMATOID ARTHRITIS,NCT04068246,Early Phase 1,0.0017979175100818997,0.998202082489918
CN(C)C(=N)NC(=N)N,_METFORMIN,CHRONIC KIDNEY DISEASES,NCT03831464,Phase 3,0.0017979175100818997,0.998202082489918
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,NEOPLASMS,NCT02964013,Phase 1,0.3201376977414728,0.6798623022585271
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,COLORECTAL CANCER,NCT02588781,Phase 2,0.2900532506128606,0.7099467493871393
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.1390735383170605,0.8609264616829395
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,COLORECTAL CANCER,NCT03957902,Phase 2,0.0743023230182084,0.9256976769817916
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,SEPSIS,NCT01784159,Phase 2,0.00714321903928667,0.9928567809607134
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.20358287994365776,0.7964171200563424
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,OVARIAN CANCER,NCT03378297,Early Phase 1,0.1390735383170605,0.8609264616829395
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,COLORECTAL CANCER,NCT03957902,Phase 2,0.0743023230182084,0.9256976769817916
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,SEPSIS,NCT01784159,Phase 2,0.00714321903928667,0.9928567809607134
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.20358287994365776,0.7964171200563424
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,_MORPHINE,ABORTION IN FIRST TRIMESTER,NCT03751423,Phase 3,0.03864591178624595,0.961354088213754
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,_MORPHINE,CESAREAN SECTION,NCT03427463,Early Phase 1,0.005566057960458478,0.9944339420395416
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,ERECTILE DYSFUNCTION|PROSTATE CANCER,NCT03406169,Phase 3,0.4310217957124737,0.5689782042875262
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,BREAST CANCER,NCT02958852,Phase 2,0.03015816108198576,0.969841838918014
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,COLORECTAL CANCER,NCT04151355,Not Applicable,0.0065643073084258345,0.9934356926915741
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,_FEXOFENADINE,GASTROESOPHAGEAL REFLUX,NCT03425097,Phase 2,0.16034550731066133,0.8396544926893387
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,RHEUMATOID ARTHRITIS,NCT03770702,Phase 3,0.033683272269207434,0.9663167277307926
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,MULTIPLE SCLEROSIS,NCT03161028,Phase 2,0.16139492420593626,0.8386050757940641
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,BREAST CANCER,NCT02897700,Phase 1,0.12515620438792752,0.8748437956120724
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,HIV INFECTION,NCT04425902,Phase 1,0.31658653157660466,0.6834134684233955
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,PREECLAMPSIA,NCT03648970,Phase 2,0.06881115876728985,0.93118884123271
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,NCT04284657,Phase 2,0.09111486562400234,0.9088851343759976
COCCc1ccc(OCC(O)CNC(C)C)cc1,_METOPROLOL,HIV INFECTION,NCT04425902,Phase 1,0.3081190676260097,0.6918809323739906
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,HIV INFECTION,NCT04425902,Phase 1,0.33434126518933543,0.6656587348106646
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,_DIGOXIN,HIV INFECTION,NCT04425902,Phase 1,0.25775469947441204,0.7422453005255882
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,_DIGOXIN,ACUTE HEART FAILURE,NCT02544815,Phase 3,0.10600139708176723,0.8939986029182327
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,HIV INFECTION,NCT04425902,Phase 1,0.2585650340817822,0.7414349659182179
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.18028491475105649,0.8197150852489434
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,OVARIAN HYPERSTIMULATION SYNDROME,NCT03794037,Phase 2,0.16062170405495682,0.8393782959450431
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,PAIN,NCT02793375,Phase 3,0.20582160309634592,0.7941783969036541
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,BREAST CANCER,NCT04172220,Not Applicable,0.02952569167889677,0.970474308321103
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,HIV INFECTION,NCT04425902,Phase 1,0.2422432593450496,0.7577567406549504
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,FATIGUE,NCT04141696,Phase 1|Phase 2,0.15831898480314466,0.8416810151968552
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+],_SODIUM_CITRATE,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,NCT04284657,Phase 2,0.2024023878331153,0.7975976121668849
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,_ROSUVASTATIN,OVARIAN CANCER,NCT03532139,Phase 2,0.3568847341163267,0.6431152658836732
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,_EZETIMIBE,CHRONIC HEPATITIS C,NCT02971033,Phase 2,0.2416159006806653,0.7583840993193348
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,MYOCARDIAL INFARCTION,NCT03715998,Phase 2,0.05001608403795045,0.9499839159620496
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_IRBESARTAN,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,NCT03493685,Phase 3,0.09783874327612327,0.9021612567238768
c1cnc2cc3c(cc2n1)C1CNCC3C1,_VARENICLINE,CANNABIS USE DISORDER,NCT03980561,Phase 2,0.2182480047783395,0.7817519952216607
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,BREAST CANCER,NCT03109990,Not Applicable,0.010191560617854143,0.9898084393821458
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,INFECTIVE ENDOCARDITIS,NCT02698930,Not Applicable,0.00294407513661018,0.9970559248633896
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,ANALGESIA,NCT04442906,Not Applicable,0.013909715994780272,0.9860902840052198
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,KIDNEY TRANSPLANTATION,NCT03327389,Not Applicable,0.00294407513661018,0.9970559248633896
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,ACUTE MYELOID LEUKEMIA,NCT04173585,Phase 2,0.2377738708294896,0.7622261291705102
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,_CELECOXIB,BLADDER CANCER,NCT02885974,Phase 1,0.5627938832722262,0.4372061167277739
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,_CELECOXIB,ANALGESIA,NCT03974932,Phase 3,0.5510703471089105,0.4489296528910897
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ACUTE MYELOID LEUKEMIA,NCT02013648,Phase 3,0.3262386977942732,0.6737613022057266
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,CHRONIC KIDNEY DISEASE,NCT02848131,Phase 2,0.3894599279586856,0.6105400720413143
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,_COBIMETINIB,NON SMALL CELL LUNG CANCER,NCT03178552,Phase 2|Phase 3,0.6037918545905582,0.3962081454094418
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,_PANOBINOSTAT,HIV INFECTION,NCT02471430,Phase 1|Phase 2,0.3385442387746708,0.6614557612253293
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,_CABOZANTINIB,NON SMALL CELL LUNG CANCER,NCT04131543,Phase 2,0.6983775738179828,0.3016224261820172
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,_CABOZANTINIB,METASTATIC RENAL CELL CARCINOMA,NCT03149822,Phase 1|Phase 2,0.8390080278147856,0.16099197218521424
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,_CABOZANTINIB,"CARCINOMA, RENAL CELL",NCT04338269,Phase 3,0.8966558993470248,0.1033441006529751
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,_CABOZANTINIB,BLADDER CANCER,NCT04289779,Phase 2,0.8510066948400464,0.14899330515995365
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,NON SMALL CELL LUNG CANCER,NCT03087448,Phase 1|Phase 2,0.738886067565545,0.26111393243445513
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,NON SMALL CELL LUNG CANCER,NCT03829332,Phase 3,0.7398283565595933,0.2601716434404067
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,BREAST CANCER,NCT03168074,Phase 2,0.7515704539186171,0.2484295460813827
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,_ABEMACICLIB,PROSTATE CANCER,NCT03706365,Phase 2,0.63434555859175,0.36565444140825004
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,_ABEMACICLIB,BREAST CANCER,NCT04565054,Phase 3,0.5291986890413407,0.4708013109586594
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,_ABEMACICLIB,BLADDER CANCER,NCT03837821,Early Phase 1,0.6346924285981429,0.3653075714018572
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,NON SMALL CELL LUNG CANCER,NCT03874000,Phase 2,0.35979023369903645,0.6402097663009638
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,BREAST CANCER,NCT04170465,Phase 2,0.07407889023746991,0.92592110976253
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,HEART FAILURE,NCT03331861,Phase 2,0.2061372510113668,0.7938627489886332
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,CHRONIC KIDNEY DISEASES,NCT03831464,Phase 3,0.0687118890128812,0.9312881109871188
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,_CLARITHROMYCIN,PARKINSON'S DISEASE,NCT03440112,Phase 1|Phase 2,0.24049418535638026,0.7595058146436199
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,_SELINEXOR,NON SMALL CELL LUNG CANCER,NCT03095612,Phase 1|Phase 2,0.8185940141859209,0.18140598581407896
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,PROSTATE CANCER,NCT02643667,Phase 1|Phase 2,0.6098283719891291,0.3901716280108712
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,METASTATIC RENAL CELL CARCINOMA,NCT04049344,Phase 2,0.5717375764905153,0.4282624235094848
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,INFERTILITY,NCT03824340,Not Applicable,0.022716045379885284,0.9772839546201146
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,PCOS,NCT04213677,Phase 3,0.08925582042289383,0.910744179577106
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.16122126348374816,0.8387787365162518
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,_EXENATIDE,PARKINSON'S DISEASE,NCT04305002,Phase 2,0.07562060888914374,0.9243793911108562
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,_DICLOFENAC,BREAST CANCER,NCT04511832,Not Applicable,0.24052939828598716,0.7594706017140129
CC(C)Cc1ccc(C(C)C(=O)O)cc1,_IBUPROFEN,ANALGESIA,NCT03955211,Phase 2,0.3474267552369893,0.6525732447630108
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,_FLUCONAZOLE,CRYPTOCOCCAL MENINGITIS,NCT03945448,Phase 2|Phase 3,0.13439917744777927,0.8656008225522207
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,_TRIMETHOPRIM,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.454663176469693,0.5453368235303069
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,_TAZEMETOSTAT,METASTATIC PROSTATE CANCER,NCT04179864,Phase 1,0.7035590209793486,0.29644097902065153
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,_CIPROFLOXACIN,PNEUMONIA,NCT03177720,Phase 1,0.003623429051267515,0.9963765709487324
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,_CIPROFLOXACIN,NEPHROLITHIASIS,NCT04374188,Not Applicable,0.003623429051267515,0.9963765709487324
CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,_CLINDAMYCIN,"INFERTILITY, FEMALE",NCT03363828,,0.2807791789274671,0.7192208210725329
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,INFECTION,NCT03844776,Not Applicable,0.1463650633329407,0.8536349366670593
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,PERIODONTITIS,NCT03733379,Phase 3,0.07030985379836825,0.9296901462016316
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,PREECLAMPSIA,NCT03724838,Not Applicable,0.016659161554578653,0.9833408384454212
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,CYSTIC FIBROSIS,NCT04039087,Phase 2|Phase 3,0.11212545888651773,0.8878745411134823
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,ERECTILE DYSFUNCTION|PROSTATE CANCER,NCT03406169,Phase 3,0.34202827466571023,0.6579717253342898
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,BRONCHOPULMONARY DYSPLASIA,NCT03142568,Phase 2,0.2112232489988544,0.7887767510011454
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,PREECLAMPSIA,NCT03724838,Not Applicable,0.040898846254324564,0.9591011537456756
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,_APIXABAN,RENAL INSUFFICIENCY,NCT02664155,Phase 3,0.17277750954192406,0.8272224904580758
CCCC(CCC)C(=O)O,_VALPROIC_ACID,ACUTE MYELOID LEUKEMIA,NCT01369368,Phase 1|Phase 2,0.19579433690004008,0.8042056630999599
Cc1ccc(=O)n(-c2ccccc2)c1,_PIRFENIDONE,RENAL INSUFFICIENCY,NCT04126538,Phase 1,0.1849194994841264,0.8150805005158737
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_CHLOROQUINE,ATRIAL FIBRILLATION,NCT02932007,Phase 2,0.4113671447731497,0.5886328552268502
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O,_CHLOROQUINE_PHOSPHATE,ATRIAL FIBRILLATION,NCT02932007,Phase 2,0.5579843788704867,0.44201562112951337
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,_PROCALCITONIN,PNEUMONIA,NCT03711227,,0.5291079072320989,0.470892092767901
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,_PROCALCITONIN,"KIDNEY FAILURE, CHRONIC",NCT03698877,,0.5291079072320989,0.470892092767901
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAMPIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.14631554544051528,0.8536844545594847
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAMPICIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.14631554544051528,0.8536844545594847
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,PARKINSON'S DISEASE,NCT04342273,Phase 1,0.2851002288129851,0.7148997711870153
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,DIABETES,NCT01984827,Phase 1,0.3017594623828985,0.6982405376171016
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,_IMIPENEM,PNEUMONIA,NCT03177720,Phase 1,0.11220809922888277,0.8877919007711172
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,_ROFLUMILAST,ASTHMA,NCT04108377,Phase 1,0.2506324890803129,0.7493675109196871
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,INFECTION,NCT03844776,Not Applicable,0.18509422879915205,0.8149057712008481
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,PERIODONTITIS,NCT03733379,Phase 3,0.04615184042148025,0.95384815957852
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,BACTERIAL VAGINOSES,NCT03954990,Phase 1,0.06592273877043357,0.9340772612295666
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,LIVER CIRRHOSIS,NCT03005444,Not Applicable,0.13242457815936373,0.8675754218406362
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,RENAL INSUFFICIENCY,NCT02664155,Phase 3,0.14978369911339776,0.8502163008866022
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,TYPE 1 DIABETES,NCT03228732,Early Phase 1,0.13777910425743906,0.8622208957425609
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,_ERTAPENEM,URINARY TRACT INFECTIONS,NCT03218800,Phase 3,0.08804005244288682,0.9119599475571132
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,_ERTAPENEM,GONORRHEA,NCT03294395,Phase 3,0.08804005244288682,0.9119599475571132
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,NEPHROLITHIASIS,NCT04374188,Not Applicable,0.02664033015920697,0.9733596698407928
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.02664033015920697,0.9733596698407928
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT02067780,Phase 2,0.02664033015920697,0.9733596698407928
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,HYPERTENSION,NCT02133872,Phase 1,0.26459628259295664,0.7354037174070435
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.4097528036875559,0.5902471963124443
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,_CAPSAICIN,PARKINSON'S DISEASE,NCT03321019,,0.515417380970624,0.4845826190293761
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,_CEPHALEXIN,CYSTIC FIBROSIS,NCT04553419,Phase 3,0.06463149676930627,0.935368503230694
Oc1ncnc2[nH]ncc12,_ALLOPURINOL,CHRONIC KIDNEY DISEASE,NCT03990363,Phase 2,0.2045200138735795,0.7954799861264206
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.4475406673406576,0.5524593326593424
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,PROSTATE CANCER,NCT02944201,Phase 2,0.3490357028541108,0.6509642971458891
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,BREAST CANCER,NCT03879629,Phase 2,0.3345232187259057,0.6654767812740946
N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,_LIOTHYRONINE,HYPOTHYROIDISM,NCT03053115,Phase 2|Phase 3,0.14711439613881985,0.8528856038611801
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,_MOMETASONE,SICKLE CELL DISEASE,NCT03758950,Phase 2,0.311809808112114,0.6881901918878858
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,HEART FAILURE,NCT02421341,Not Applicable,0.03624057985355136,0.9637594201464488
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,ANALGESIA,NCT04442906,Not Applicable,0.019190704368712872,0.9808092956312869
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,ABORTION IN FIRST TRIMESTER,NCT03751423,Phase 3,0.026867950579050327,0.9731320494209496
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,PRURITIS,NCT04518618,Not Applicable,0.006891088025846201,0.9931089119741536
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,COLORECTAL CANCER,NCT03273231,Not Applicable,0.003678138272299636,0.9963218617277004
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,FATIGUE,NCT04141696,Phase 1|Phase 2,0.1739361126777982,0.8260638873222017
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,ABORTION IN FIRST TRIMESTER,NCT03751423,Phase 3,0.03641808369874214,0.963581916301258
FCOC(C(F)(F)F)C(F)(F)F,_SEVOFLURANE,ATRIAL FIBRILLATION,NCT02697448,Not Applicable,0.07383115881403088,0.9261688411859692
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,DIABETIC FOOT,NCT03871049,Not Applicable,0.004242409985845944,0.995757590014154
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,ANALGESIA,NCT03922048,Phase 2,0.1056661434846684,0.8943338565153315
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,UTERINE FIBROIDS,NCT04068766,Not Applicable,0.006842920054239136,0.993157079945761
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,CESAREAN SECTION,NCT03498118,Not Applicable,0.006031037571211973,0.993968962428788
CC(C)c1cccc(C(C)C)c1O,_PROPOFOL,ATRIAL FIBRILLATION,NCT02697448,Not Applicable,0.06792333728645747,0.9320766627135426
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,_OXYCODONE,PARKINSON'S DISEASE,NCT02601586,Phase 2|Phase 3,0.01985658067586251,0.9801434193241374
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,_OXYCODONE,NEPHROLITHIASIS,NCT03584373,Phase 3,0.04514575843787785,0.9548542415621224
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,_OXYCODONE,COLORECTAL CANCER,NCT03253133,Phase 1,0.18255158138942915,0.8174484186105707
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,_DIAZEPAM,CONTRACEPTION,NCT02799641,Not Applicable,0.14007801477483026,0.8599219852251698
O=C([O-])O.[Na+],_SODIUM_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.17147029368000158,0.8285297063199987
O=C(O)O,_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.26534254809762314,0.7346574519023769
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,BLADDER CANCER,NCT01935466,,0.2491157244953053,0.7508842755046947
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.32673850886395883,0.6732614911360413
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,ACUTE MYELOID LEUKEMIA,NCT02942758,Phase 2,0.06260518024909863,0.9373948197509012
O=S(=O)(O)CCS,_MESNA,SICKLE CELL DISEASE,NCT03263559,Phase 2,0.7754258801779708,0.22457411982202932
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,PREECLAMPSIA,NCT02221830,Early Phase 1,0.0075649361001358904,0.9924350638998639
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,CESAREAN SECTION COMPLICATIONS,NCT03777878,Not Applicable,0.0019789486642865935,0.9980210513357136
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,POSTOPERATIVE PAIN,NCT03011307,Phase 2,0.015009631936063503,0.9849903680639364
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,_ROCURONIUM,PROSTATE CANCER,NCT03808077,Phase 2,0.10458097112906058,0.8954190288709395
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,_KETOROLAC,NEPHROLITHIASIS,NCT03584373,Phase 3,0.027805708368477004,0.9721942916315228
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,_NALBUPHINE,POSTOPERATIVE COMPLICATIONS,NCT03470077,Phase 2,0.09848245454825473,0.9015175454517456
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,_IOHEXOL,ACUTE KIDNEY INJURY,NCT02772276,Phase 2,0.24439941601668036,0.7556005839833196
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,_IOHEXOL,ACUTE RENAL FAILURE,NCT02961478,Phase 3,0.2143882655050492,0.7856117344949509
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,_IOHEXOL,RENAL DISEASE,NCT03578523,,0.2692366086562968,0.7307633913437033
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,POSTOPERATIVE PAIN,NCT04544228,Not Applicable,0.09294232904742723,0.9070576709525728
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,_TENOFOVIR_ALAFENAMIDE,HIV-1 INFECTION,NCT04301661,,0.32396299058496714,0.6760370094150329
COc1cc(CC(C)N)c(OC)cc1C,_DOM,STROKE,NCT03828851,Not Applicable,0.1314119912225934,0.8685880087774066
COc1cc(CC(C)N)c(OC)cc1C,_DOM,HEMOPHILIA A,NCT03818763,Phase 1,0.4851632497920704,0.5148367502079295
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,PELVIC ORGAN PROLAPSE,NCT03216083,Phase 3,0.03995970132391799,0.960040298676082
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,BLADDER CANCER,NCT01869413,Phase 2|Phase 3,0.034959701323917985,0.965040298676082
C[C@@H]1O[C@@H]1P(=O)(O)O,_FOSFOMYCIN,GONORRHEA,NCT03294395,Phase 3,0.01904442289384775,0.980955577106152
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,_MITOMYCIN,COLORECTAL CANCER,NCT02614534,Phase 3,0.09402344860011802,0.9059765513998822
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,_VANDETANIB,NEOPLASMS,NCT02530411,Phase 2,0.7147599755826063,0.28524002441739393
[Cl-].[K+],_POTASSIUM_CHLORIDE,HEART FAILURE,NCT02840799,Phase 2,0.26211980232498494,0.737880197675015
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],_MAGNESIUM_CITRATE,DIABETIC NEPHROPATHY,NCT03824379,Phase 2,0.09821742980757524,0.9017825701924248
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,_CRIZOTINIB,NON SMALL CELL LUNG CANCER,NCT03375242,,0.8105587467336531,0.18944125326634695
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,_CRIZOTINIB,NEOPLASMS,NCT03194893,Phase 3,0.7265991703662091,0.2734008296337907
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,NON SMALL CELL LUNG CANCER,NCT03267654,Phase 2,0.3517776280541271,0.6482223719458731
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,COLORECTAL CANCER,NCT04446091,Phase 1|Phase 2,0.19524460753893835,0.8047553924610614
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,NON SMALL CELL LUNG CANCER,NCT03267654,Phase 2,0.3517776280541271,0.6482223719458731
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,COLORECTAL CANCER,NCT04446091,Phase 1|Phase 2,0.19524460753893835,0.8047553924610614
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,OVARIAN CANCER,NCT03763123,Phase 1,0.8101887158945934,0.18981128410540649
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],_NIFEDIPINE,CHRONIC KIDNEY DISEASES,NCT03695107,,0.2819097297364406,0.7180902702635596
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],_NIFEDIPINE,PRETERM PREMATURE RUPTURE OF MEMBRANE,NCT03976063,Phase 3,0.023790201575160267,0.9762097984248398
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,_TALAZOPARIB,BREAST CANCER,NCT04039230,Phase 1|Phase 2,0.8129631314898355,0.18703686851016466
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,_TALAZOPARIB,ACUTE MYELOID LEUKEMIA,NCT02878785,Phase 1|Phase 2,0.8294543071234222,0.1705456928765778
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,END STAGE RENAL DISEASE,NCT03713190,Phase 2,0.09251803684162473,0.9074819631583751
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,TYPE 1 DIABETES,NCT04201496,Phase 1,0.31905453569474784,0.6809454643052522
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,CHRONIC KIDNEY DISEASE,NCT03594110,Phase 3,0.2095275236817926,0.7904724763182074
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,GESTATIONAL DIABETES,NCT03215069,Phase 3,0.15608016960451773,0.8439198303954822
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,ACUTE DECOMPENSATED HEART FAILURE,NCT04049045,Phase 2,0.1382858954214974,0.8617141045785026
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,_ERTUGLIFLOZIN,TYPE 2 DIABETES,NCT04029480,Phase 3,0.42082015900139297,0.5791798409986071
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,_MARAVIROC,STROKE,NCT03172026,Phase 2|Phase 3,0.0580249560596535,0.9419750439403468
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.2051830111331826,0.7948169888668174
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.2051830111331826,0.7948169888668174
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,PARKINSON'S DISEASE,NCT04164758,Phase 2,0.32486063296029644,0.6751393670397033
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,_APREPITANT,NON SMALL CELL LUNG CANCER,NCT02646020,Phase 2,0.2280298687417159,0.7719701312582843
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,_CETIRIZINE,CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME,NCT03167216,Early Phase 1,0.5314490506716956,0.4685509493283045
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,_MEGESTROL_ACETATE,BREAST CANCER,NCT03306472,Phase 2,0.24984673714599506,0.7501532628540051
NCCCC[C@H](N)C(=O)O,_LYSINE,HEART FAILURE,NCT03446651,Early Phase 1,0.4447136393667435,0.5552863606332565
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,_ARTESUNATE,COLORECTAL CANCER,NCT03093129,Phase 2,0.09656653080069096,0.9034334691993092
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],_PEMETREXED_DISODIUM,NON SMALL CELL LUNG CANCER,NCT04379635,Phase 3,0.28274602290890505,0.7172539770910952
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,_DOBUTAMINE,MYOCARDIAL INFARCTION,NCT03289728,Not Applicable,0.07800652177561512,0.9219934782243848
NCCc1c[nH]c2ccc(O)cc12,_SEROTONIN,DEPRESSION,NCT03222570,Phase 2,0.3472212362234992,0.652778763776501
NCCc1c[nH]c2ccc(O)cc12,_SEROTONIN,STROKE,NCT02865642,Phase 2,0.08355364221668207,0.916446357783318
CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,_DYDROGESTERONE,PRETERM BIRTH,NCT03428685,Phase 2|Phase 3,0.03798524829193943,0.9620147517080606
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,_EPLERENONE,HIV INFECTION,NCT02740179,Not Applicable,0.1885019531700583,0.8114980468299415
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,_EPLERENONE,END-STAGE RENAL DISEASE,NCT02490904,Phase 3,0.11340462209480574,0.8865953779051943
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,NEPHROTIC SYNDROME,NCT03750136,Not Applicable,0.01622165223638013,0.9837783477636198
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,_ESTROGEN,URINARY TRACT INFECTIONS,NCT04301934,Not Applicable,0.030073463859472606,0.9699265361405274
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,_ESTROGEN,PELVIC ORGAN PROLAPSE,NCT01648751,Not Applicable,0.12899565891396347,0.8710043410860366
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,_ALPRAZOLAM,TYPE 1 DIABETES,NCT03635437,Phase 1|Phase 2,0.104692348613657,0.895307651386343
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,_MUPIROCIN,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.3158029743652381,0.6841970256347616
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,BREAST CANCER,NCT02395614,Not Applicable,0.2706008552895812,0.7293991447104188
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,INFECTION,NCT03844776,Not Applicable,0.11279045681441102,0.8872095431855891
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.4522472466126027,0.5477527533873974
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,PRETERM PREMATURE RUPTURE OF MEMBRANE,NCT04516226,Not Applicable,0.1569224388463769,0.8430775611536231
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_CHLORHEXIDINE_GLUCONATE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.4717792179549965,0.5282207820450034
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_CHLORHEXIDINE_GLUCONATE,PRETERM PREMATURE RUPTURE OF MEMBRANE,NCT04516226,Not Applicable,0.14438683333633476,0.855613166663665
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,_SULFAMETHOXAZOLE,CYSTIC FIBROSIS,NCT03489629,Phase 2,0.5832246364543385,0.4167753635456617
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,_ZOLPIDEM,PROSTATIC NEOPLASMS,NCT03436745,Phase 1,0.2466296742132239,0.7533703257867762
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,_CEDIRANIB,NON SMALL CELL LUNG CANCER,NCT03334617,Phase 2,0.6959532272197957,0.3040467727802041
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_BETAMETHASONE,PREMATURE BIRTH,NCT02469519,Phase 2|Phase 3,0.047017604317723935,0.9529823956822764
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,SICKLE CELL DISEASE,NCT03978156,Phase 1,0.2002980544813705,0.7997019455186295
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,_RIBAVIRIN,ACUTE MYELOID LEUKEMIA,NCT03760666,Phase 1|Phase 2,0.19601749639708235,0.8039825036029177
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,PARKINSON'S DISEASE,NCT03575195,Phase 1|Phase 2,0.17444220056065055,0.8255577994393498
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,TYPE 2 DIABETES,NCT03758144,Not Applicable,0.1381836248754417,0.8618163751245583
NC(=O)NO,_HYDROXYUREA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.3479937799410577,0.6520062200589425
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,_PENTOSTATIN,SICKLE CELL DISEASE,NCT03077542,Phase 1|Phase 2,0.7704369487554775,0.2295630512445228
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,_IDASANUTLIN,COLORECTAL CANCER,NCT03555149,Phase 1|Phase 2,0.6897060926525139,0.31029390734748624
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,BREAST CANCER,NCT03911453,Early Phase 1,0.6421709569678467,0.3578290430321533
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,PROSTATE CANCER METASTATIC,NCT03413995,Phase 2,0.69835884358263,0.3016411564173699
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,NCT04253262,Phase 1|Phase 2,0.6551343055073969,0.344865694492603
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,_ZAFIRLUKAST,OVARIAN CANCER,NCT04339140,Phase 2,0.6604830674309337,0.3395169325690663
FC(F)(F)C(F)(F)C(F)(F)F,_PERFLUTREN,KIDNEY CANCER,NCT04021238,Phase 2,0.4228862838526457,0.5771137161473545
FS(F)(F)(F)(F)F,_SULFUR_HEXAFLUORIDE,KIDNEY CANCER,NCT04021238,Phase 2,0.49468750195470507,0.505312498045295
O=[As]O[As]=O,_ARSENIC_TRIOXIDE,HIV/AIDS,NCT03980665,Phase 1,0.1139596204955768,0.8860403795044234
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,_SOLIFENACIN,OVERACTIVE BLADDER|PARKINSON DISEASE,NCT03149809,Phase 3,0.04792611107707627,0.9520738889229236
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,_FLUTICASONE,PHARMACOKINETICS,NCT03739294,Phase 2,0.2105700588940469,0.7894299411059531
CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3],_GADOTERIDOL,MULTIPLE SCLEROSIS,NCT03396822,,0.3898951718891073,0.610104828110893
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,CORONARY ARTERY DISEASE,NCT02954510,Phase 3,0.518985649407416,0.4810143505925841
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,HYPERTENSION,NCT02425566,Phase 1,0.36916415999643104,0.630835840003569
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,ACUTE HEART FAILURE,NCT03302910,Phase 2|Phase 3,0.1094526765270873,0.8905473234729127
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,PROSTATE CANCER,NCT03716739,Phase 2,0.070812989983703,0.9291870100162972
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,LIVER CIRRHOSIS,NCT03995251,Not Applicable,0.01394681380162269,0.9860531861983772
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,_TESTOSTERONE_CYPIONATE,PROSTATE CANCER,NCT03716739,Phase 2,0.2179999377830461,0.7820000622169537
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_ENANTHATE,PROSTATE CANCER,NCT02090114,Phase 2,0.4537853263140117,0.5462146736859882
N[C@]1(C(=O)O)C[C@@H](F)C1,_FLUCICLOVINE,PROSTATE CANCER,NCT04009083,Not Applicable,0.2351606525119581,0.7648393474880417
N[C@]1(C(=O)O)C[C@@H](F)C1,_FLUCICLOVINE,PROSTATE ADENOCARCINOMA,NCT03762759,Phase 2,0.3117773298350979,0.6882226701649019
OC[C@H]1O[C@H](O[C@]2(CO[C@]3(CO[C@]4(CO[C@]5(CO[C@]6(CO[C@]7(CO[C@]8(CO[C@]9(CO[C@]%10(CO[C@]%11(CO[C@]%12(CO[C@]%13(CO[C@]%14(CO[C@]%15(CO[C@]%16(CO[C@]%17(CO[C@]%18(CO[C@]%19(CO[C@]%20(CO[C@]%21(CO[C@]%22(CO[C@]%23(CO[C@]%24(CO[C@]%25(CO[C@]%26(CO[C@]%27(CO[C@]%28(CO[C@]%29(CO[C@]%30(CO[C@]%31(CO[C@]%32(CO[C@]%33(CO[C@]%34(CO[C@]%35(CO[C@]%36(CO[C@]%37(CO[C@]%38(CO)O[C@H](CO)[C@@H](O)[C@@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_INULIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04459156,Not Applicable,0.20244271701374789,0.7975572829862523
C=CCN.ClCC1CO1,_SEVELAMER,CHRONIC KIDNEY DISEASES,NCT04120922,Not Applicable,0.22323811887804496,0.7767618811219549
C=CCN.ClCC1CO1,_SEVELAMER,HYPERPHOSPHATEMIA,NCT04551300,Phase 2,0.09432783647832524,0.9056721635216748
C=CC[NH3+].ClCC1CO1.O=C([O-])O,_SEVELAMER_CARBONATE,CHRONIC KIDNEY DISEASES,NCT04120922,Not Applicable,0.3105766784206198,0.6894233215793798
C=CC[NH3+].ClCC1CO1.O=C([O-])O,_SEVELAMER_CARBONATE,HYPERPHOSPHATEMIA,NCT04551300,Phase 2,0.2275636596842417,0.7724363403157584
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,NON SMALL CELL LUNG CANCER,NCT02570815,Phase 1,0.20348786896277266,0.7965121310372275
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,RHEUMATOID ARTHRITIS,NCT02680067,Phase 1,0.3947149571413273,0.6052850428586729
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,ENDOMETRIOSIS,NCT03950206,Not Applicable,0.1344527249860987,0.8655472750139013
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,_TAMSULOSIN,URINARY RETENTION,NCT03609580,Phase 1|Phase 2,0.3011157747864284,0.6988842252135715
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl,_TAMSULOSIN_HYDROCHLORIDE,URINARY RETENTION,NCT03314025,Phase 2,0.04083519836044285,0.9591648016395572
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],_POTASSIUM_CITRATE,KIDNEY STONES,NCT03281928,Not Applicable,0.19213338231604404,0.8078666176839561
O=[N+]([O-])[O-],_NITRATE,HEART FAILURE,NCT02840799,Phase 2,0.25158959611517856,0.7484104038848216
O=[N+]([O-])[O-],_NITRATE,ERECTILE DYSFUNCTION,NCT04116060,Not Applicable,0.12377528565379622,0.8762247143462036
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,NON SMALL CELL LUNG CANCER,NCT02642939,Phase 2,0.26860758556956776,0.7313924144304322
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,BREAST CANCER,NCT02788981,Phase 2,0.1087082253006491,0.8912917746993511
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,_DONEPEZIL,"DIABETES MELLITUS, TYPE 2",NCT04507438,Phase 2,0.2044819166203476,0.7955180833796526
CC(=O)C(=O)O,_PYRUVATE,PROSTATE CANCER,NCT02913131,Phase 1|Phase 2,0.4365596215394255,0.5634403784605745
CC(=O)C(=O)O,_PYRUVATE,BREAST CANCER,NCT03121989,Phase 1,0.2252195751149597,0.7747804248850403
CC(=O)C(=O)O,_PYRUVATE,PROSTATE ADENOCARCINOMA,NCT03933670,Phase 2,0.5409932971088545,0.4590067028911457
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,_PACRITINIB,BREAST CANCER,NCT04520269,Phase 1|Phase 2,0.554063910305822,0.4459360896941781
CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1,_ATOSIBAN,"INFERTILITY, FEMALE",NCT03904745,Not Applicable,0.024164397392697462,0.9758356026073024
CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1,_ATOSIBAN,PRETERM LABOR,NCT03369262,Phase 2,0.11311335069197702,0.8868866493080231
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,_BUMETANIDE,PARKINSON'S DISEASE,NCT03899324,Phase 2,0.1917818593726405,0.8082181406273592
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,_GRANISETRON,SEPSIS,NCT03924518,Phase 2,0.07773213975260336,0.9222678602473968
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,_LEVOSIMENDAN,ST ELEVATION MYOCARDIAL INFARCTION,NCT03699215,Phase 3,0.05001160883493209,0.9499883911650678
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,_LEVOSIMENDAN,ACUTE DECOMPENSATED HEART FAILURE,NCT04158674,Phase 3,0.05001160883493209,0.9499883911650678
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,_LEVOSIMENDAN,"CARDIAC OUTPUT, LOW",NCT04179604,Phase 2|Phase 3,0.15445926441073676,0.8455407355892632
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_CARBETOCIN,CESAREAN SECTION COMPLICATIONS,NCT03777878,Not Applicable,0.007312194639399523,0.9926878053606004
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,_OXYMETAZOLINE,FECAL INCONTINENCE,NCT03529487,Phase 1,0.3446320917509545,0.6553679082490454
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,_TOLTERODINE,PELVIC ORGAN PROLAPSE,NCT02599311,Phase 3,0.1107723665646584,0.8892276334353417
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,_ILOPROST,"RESPIRATORY DISTRESS SYNDROME, ADULT",NCT03111212,Phase 3,0.1222205867431611,0.8777794132568388
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,_TERAZOSIN,PARKINSON'S DISEASE,NCT03905811,Phase 1|Phase 2,0.2020313454791556,0.7979686545208444
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,_ALBUTEROL_SULFATE,ASTHMA,NCT03847896,Phase 3,0.4733134577610884,0.5266865422389116
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,_PIMAVANSERIN,PARKINSON'S DISEASE,NCT04164758,Phase 2,0.3133305596785244,0.6866694403214757
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,_FOSTAMATINIB,OVARIAN CANCER,NCT03246074,Phase 1,0.7096752549378244,0.29032474506217576
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,_AFURESERTIB,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,NCT04060394,Phase 1|Phase 2,0.6246114318905818,0.3753885681094184
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,_SEMAGLUTIDE,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.17430366983516776,0.8256963301648322
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,_SALSALATE,PCOS,NCT03229408,Phase 2,0.3623224687105676,0.6376775312894322
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,_SALSALATE,PREECLAMPSIA,NCT03482440,Early Phase 1,0.2657229859276318,0.7342770140723683
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,PAIN,NCT04313179,Not Applicable,0.059988633772234734,0.9400113662277652
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,_GENISTEIN,BLADDER CANCER,NCT01489813,Phase 2,0.5555192817269267,0.4444807182730734
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,PAIN,NCT04132609,Not Applicable,0.6215958732176899,0.37840412678231
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,CANNABIS USE DISORDER,NCT03629990,Not Applicable,0.40447872557125897,0.5955212744287409
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,ANXIETY,NCT04245501,Not Applicable,0.6214855938113246,0.3785144061886754
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,_LINOLEIC_ACID,CYSTIC FIBROSIS,NCT04531410,Not Applicable,0.25362717726057243,0.7463728227394276
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,_FLUTICASONE_FUROATE,PHARMACOKINETICS,NCT03739294,Phase 2,0.2121527154021488,0.7878472845978512
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,_CANAGLIFLOZIN,HEART FAILURE,NCT04252287,Phase 3,0.14911273949652715,0.8508872605034729
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,_BICTEGRAVIR,HIV/AIDS,NCT03789968,,0.22824550996672566,0.7717544900332743
Cc1ncc(CO)c(CN)c1O,_PYRIDOXAMINE,"DIABETES MELLITUS, TYPE 2",NCT03778580,Not Applicable,0.2062476296963521,0.7937523703036482
C[S@@](=O)CCCCN=C=S,_SULFORAPHANE,DEPRESSION,NCT04246905,Phase 2,0.2304490633921376,0.7695509366078623
O=N[O-],_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.680151929500452,0.31984807049954805
O=N[O-].[Na+],_SODIUM_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.8051596144800053,0.19484038551999475
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,_ETELCALCETIDE,END STAGE RENAL DISEASE,NCT03795558,Phase 2,0.5644995279367585,0.4355004720632414
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,_ETELCALCETIDE,SECONDARY HYPERPARATHYROIDISM|CHRONIC KIDNEY DISEASE,NCT03633708,Phase 3,0.3843899000402139,0.615610099959786
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,_HYDROXYPROGESTERONE,PRETERM BIRTH,NCT03292731,Phase 2|Phase 3,0.13716494786475136,0.8628350521352488
O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21,_VIBEGRON,OVERACTIVE BLADDER SYNDROME,NCT03902080,Phase 3,0.6156891770375538,0.3843108229624462
O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,_PIMODIVIR,"KIDNEY FAILURE, CHRONIC",NCT03947814,Phase 1,0.7083509387189596,0.2916490612810404
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,_VOXELOTOR,SICKLE CELL DISEASE,NCT04247594,Phase 2,0.30979109857824794,0.6902089014217522
C[C@@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]2N)[C@H](O)[C@@H]1O,_ELX-02,CYSTIC FIBROSIS,NCT04135495,Phase 2,0.6251185247734025,0.3748814752265974
C[C@]1([18F])C[C@@](N)(C(=O)O)C1,_FLUCICLOVINE_F18,PROSTATE ADENOCARCINOMA,NCT03762759,Phase 2,0.3555145446923075,0.6444854553076926
OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O,_D-MANNOSE,URINARY TRACT INFECTIONS,NCT03395288,Phase 2|Phase 3,0.14899262972852528,0.8510073702714748
CCCCCC1=CC(=O)C=C(OC)C1=O,_PRIMIN,STROKE,NCT03517657,Not Applicable,0.257059617358268,0.7429403826417321
NC(=O)OCC(COC(N)=O)c1ccccc1,_FELBAMATE,EPILEPSY,NCT03196466,,0.43069836150093055,0.5693016384990695
O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,_DANTROLENE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.6076358698674784,0.3923641301325215
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C,_DEOXYCHOLIC_ACID,ADIPOSITY,NCT04054011,Early Phase 1,0.4801055973195351,0.519894402680465
N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,_TIPIRACIL,COLORECTAL CANCER,NCT03974594,Phase 1,0.2729426936307986,0.7270573063692012
COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,_ENCORAFENIB,NON SMALL CELL LUNG CANCER,NCT03915951,Phase 2,0.4265036841932772,0.573496315806723
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,_LASMIDITAN,MIGRAINE DISORDERS,NCT04396574,Phase 3,0.4572507910411994,0.5427492089588007
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,BREAST CANCER,NCT03056755,Phase 2,0.5227911549038815,0.4772088450961186
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,_ERAVACYCLINE,BACTERIAL INFECTIONS,NCT03696550,Phase 1,0.3794956920950481,0.620504307904952
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,PROSTATE CANCER,NCT04136353,Phase 3,0.2749743040488291,0.7250256959511705
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,NCT04237584,Phase 3,0.3708165996405573,0.6291834003594426
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,_ENASIDENIB,ACUTE MYELOID LEUKEMIA,NCT04075747,Phase 1,0.7336723476986257,0.26632765230137445
C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,_UBROGEPANT,MIGRAINE DISORDERS,NCT04492020,Phase 3,0.3993314636815342,0.6006685363184656
